Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Procardia XL (nifedipine) extended release tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

September 2011

Summary View

WARNINGS

Gastrointestinal Obstruction Requiring Surgery
  • include alteration in gastrointestinal...diverticulitis, diverticulosis, and inflammatory bowel disease
  • ...concomitant medications: opiates...neuromuscular blocking agents.
Gastrointestinal Ulcers
  • Cases of tablet adherence to the gastrointestinal wall with ulceration have been reported, some requiring hospitalization and intervention.

ADVERSE EXPERIENCES

  • Gastrointestinal obstruction resulting in hospitalization and surgery, including the need for bezoar removal, has occurred in association with PROCARDIA XL, even in patients with no prior history of gastrointestinal disease.
  • Cases of tablet adherence to the gastrointestinal wall with ulceration have been reported, some requiring hospitalization and intervention.
  • Acute generalized exanthematous pustulosis also has been reported.

 

October 2010

Summary View

 

WARNINGS

Congestive Heart Failure
  • Patients with tight aortic stenosis may be at greater risk for such an event, as the unloading effect of nifedipine would be expected to be of less benefit, owing to the fixed impedance to flow across the aortic valve in these patients
Gastrointestinal Obstruction Requiring Surgery
  • There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of Procardia. Bezoars can occur in very rare cases and may require surgical intervention.
  • Cases of serious gastrointestinal obstruction have been identified in patients with no known gastrointestinal disease, including the need for hospitalization and surgical intervention.
  • Risk factors for gastrointestinal obstruction identified from post-marketing reports of Procardia XL (GITS tablet formulation) include alteration in gastrointestinal anatomy (severe gastrointestinal narrowing, colon cancer, small bowel obstruction, bowel resection, gastric bypass, vertical banded gastroplasty, and colostomy), hypomotility disorders (constipation, gastroesophageal reflux disease, ileus, obesity, hypothyroidism, and diabetes) and concomitant medications (H2-histamine blockers, nonsteroidal antiinflammatory drugs, laxatives, anticholinergic agents, and levothyroxine)...

PRECAUTIONS

Other
  • As with any other non-deformable material, caution should be used when administering Procardia XL in patients with pre-existing severe gastrointestinal narrowing (pathologic or iatrogenic). There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of Prcardia XL.

ADVERSE EXPERIENCES

  • Gastrointestinal obstruction resulting in hospitalization and surgery, including the need for bezoar removal, has occurred in association with Procardia XL, even in patients with no prior history of gastrointestinal disease.

 

-
-